GSK and Pfizer invested more than $50 million in oral integrated products

, a US-based start-up biotech company, recently announced the results of round A financing: multi-strategic investors bought the company's next-generation oral integrator concept for $51.5m. Notably, the first round of investments was co-led by GSK and Pfizer, with other investors including Omega Funds and AbbVie Ventures, as well as start-up investors Polaris Investments and Spglin and Shanghua Pharmaceuticals Investment Group.
The company's ability to attract the attention of a number of star investment institutions and pharmaceutical companies during the A-round financing phase is due to the fact that they have solved the technical problems that have long plagued integrative targeted therapies, turning integrators that could only be used for injectable therapies into small-molecule oral drugs, and in the chronically disease-driven field, the convenience of pills will make huge profits for drug companies, and for GSK and Pfizer they hope to further advance the immunotherapy field.is an integrated factor?
is a widely expressed family of subjects on the surface of human cells, and its signals can be involved in affecting a wide range of in-cell functions, including cell survival, cell cycle processes, cell differentiation, and cell migration.
Studies have shown that abnormal cell signals mediated by integrator are one of the factors that cause many human diseases, including Morphic Therapeutic's current research and development focus: fibrosis, autoimmune diseases, and immuno-oncology therapies, which are important disease directions that are favored in the future of biopharmaceuticals.
To take oncology immunotherapy as an example, the world's leading multinational pharmaceutical companies such as Roche, AstraZeneta, Pfizer, GlaxoSmithKline, etc. have all been involved, at present, these pharmaceutical companies choose to work with similar biotech companies in Morphic Therapeutic is the main way. On March 15 this year, Roche announced a $1 billion partnership with Blueprint Pharmaceuticals, another biotech company, to develop and commercialize five small molecule therapies that target key kinases in cancer immunotherapy.
And this time GSK and Pfizer are focused on Morphic Therapeutic, a biotech company dedicated to developing a new generation of oral integrator therapies, inspired by decades of academic research in the field of integrated hormones by its founders, Professor Timothy A. Springer of Harvard Medical School and Boston Children's Hospital.the application oftechnology has a long way to go
In the 1980s, the company's technology founder, Dr. Springer, led to the first generation of research and development projects for integratives, and six injectable integrator therapies were approved for treatment of diseases including multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, acute coronary artery syndrome, and complications during the intervention of the coronary coronary arteries.
actually, Springer's discovery spawned the emergence of six different drugs, some of which benefited from the size of the drug companies that had become very large at the time. "But because there are still a lot of problems after clinical use, a lot of pharmaceutical companies have gone downhill, and some have even finally left the industry, " Dr. Praveen Tipirneni, Morphic's president and chief executive, said in an interview. In
later studies, they found that these problems stem from the absence of an effective design to target small molecular candidates to block interactions between proteins that are integrated. With this in mind, Morphic Therapeutic has developed a unique platform for the design and development of the most promising small molecular compounds, starting with the construction and analysis of ultra-high-resolution integrative crystal structures.
Praveen Tipirnen said they will now advance two projects simultaneously - small molecules targeted by proven biologics, as well as small molecules targeted by new targets. Specific strategic investors are interested in both projects.
" is that this is the first time that Schr Dinger, a computer chemistry company, has invested a foreign investment. Praveen Tipirneni says they hope to emulate Nimbus, which is part of a partnership with Schr Dinger. This spring, Nimbus Pharmaceuticals sold the ACC (acetyl coenzyme A carbohydrase) inhibitor program to Gilead Sciences for an initial investment of $400 million, then an additional $800 million, one of the milestones in Nimbus' career.
from a physical chemical point of view, we already have the perfect small molecule preparation, but before they were not as effective as biologics. Now we know why: a theory confirms that an integrator is an astration that strengthens signaling rather than inhibition. Biologics are physically large, so they inhibit the adhesion of integrators to cells, and therefore work better. Praveen Tipirneni concludes.
", but no one used to be able to make a small molecule of allicin. Now we can lock the integratives in a closed way, with the ultimate goal of creating an unprecedented number of small molecules suitable for the integratives. In the field of chronic diseases, the convenience of pills will be a huge advantage. He added.
understand that Morphic is currently working with Schr.dinger to accelerate the development and design of candidate iterations to meet development needs using computer chemistry software